Prospects for allogeneic acellular tissue-engineered products in the management of post-ischemic myocardial remodeling
https://doi.org/10.15825/1995-1191-2026-2-188-201
Abstract
Advances in regenerative medicine have generated strong interest in the development of alternative treatments for heart failure and other cardiovascular diseases. Among these, gel-forming materials derived from decellularized extracellular matrices of various tissues have emerged as a promising avenue. However, reported outcomes of their effectiveness remain inconsistent, ranging from high to highly questionable. This may be due to differences in the tissues used to obtain the matrix, decellularization protocols and efficiency. This review summarizes current studies evaluating the potential of acellular injectable products derived from allogeneic biological sources to stimulate endogenous sanogenetic mechanisms in cardiac muscle regeneration.
About the Authors
S. A. Afanasiev
Tomsk National Research Medical Center
Russian Federation
Russian Federation
Sergey A. Afanasiev.
111a, Kievskaya str., Tomsk, 634012
Phone: (382) 255-50-57
B. A. Zakopayko
Kirov Military Medical Academy
Russian Federation
Russian Federation
St. Petersburg
D. S. Kondratieva
Tomsk National Research Medical Center
Russian Federation
Russian Federation
Tomsk
D. A. Zemlyanoy
St. Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
St. Petersburg
D. V. Raguzina
Kirov Military Medical Academy
Russian Federation
Russian Federation
St. Petersburg
S. V. Popov
Tomsk National Research Medical Center
Russian Federation
Russian Federation
Tomsk
References
1. Garganeeva AA, Kuzheleva EA, Tukish OV, Vitt KN, Andreev SL, Muslimova EF et al. Possibilities of mitochondrial dysfunction diagnosis in chronic heart failure. The siberian journal of clinical and experimental medicine. 2024; 39 (3): 51–57. https://doi.org/10.29001/2073-8552-2024-39-3-51-57.
2. Pocock S, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006; 27 (1): 65–75.
3. Ganyukov VI, Tarasov RS, Neverova YuN, Kochergin NA, Barbarash OL, Barbarash LS. Long-term results of different approaches to revascularization in non-ST-segment elevation acute coronary syndrome and multiple coronary atherosclerosis. Terapevticheskii arkhiv. 2017; 89 (4): 29–34.
4. Galli A, Lombardi F. Postinfarct Left Ventricular Remodelling: A Prevailing Cause of Heart Failure. Cardiology Research and Practice. 2016; Article ID 2579832, 12 pages http://dx.doi.org/10.1155/2016/2579832.
5. Belenkov YuN. Ways of Development of Domestic Cardiology: Results, Plans, and Hopes. AtmosferA. Cardiology. 2002; 4: 2–4.
6. Popov SV, Ryabov VV, Suslova TE, Shtatolkina MA, Vesnina GV, Krylov AL et al. Fundamental and applied aspects of sellular technoloies in cardiology and cardiosurgery. Bulletin of the Siberian section of the Russian academy of medical sciences. 2008: 28 (4): 5–15.
7. Shumakov VI, Kazakov EN, Onischenko NA, Gureev SV, Ostroumov EN, Chestuhin VV et al. The first experience of clinical application autological mezenchimal bone marrow stem cells for rehabilitation of retractive myocardial function. Russian journal of cardiology. 2003; 43 (5): 42–50.
8. Belenkov YuN, Ageev FT, Mareev VYu. Stem cells and their application for myocardial regeneration. Russian heart failure journal. 2004; 4 (4): 168–173.
9. Bokeria LA, Buziashvili YuI, Matskeplishvili ST, Kamardinov DKh. Cellular therapy for coronary artery disease; the first experience of using stem cells in patients with heart failure and acute myocardial infarction. Bulletin of the A.N. Bakulev national center for cardiovascular diseases. Cardiovascular diseases. 2004; 5 (2): 5–19.
10. Karaskov AM, Larionov PM, Chernyavsky AM, Subbotin DV, Sergeevichev DS, Fomichev AV et al. Morphofunctional and molecular-genetic assessment of the experimental results of indirect revascularization using various bone marrow-derived cells. Circulation pathology and cardiac surgery. 2007; 4: 75–81.
11. Lockhart M, Wirrig E, Phelps A, Wessels A. Extracellular matrix and heart development. Birth Defects Res Part A – Clin Mol Teratol. 2011; 91 (6): 535–550. https://doi.org/10.1002/bdra.20810.
12. Badylak SF, Taylor D, Uygun K. Whole-organ tissue engineering: decellularization and recellularization of three-dimensional matrix scaffolds. Annu Rev Biomed Eng. 2011 Aug 15; 13: 27–53. doi: 10.1146/annurev-bioeng-071910-124743.
13. Rozario T, DeSimone DW. The extracellular matrix in development and morphogenesis: a dynamic view. Dev Biol. 2010 May 1; 341 (1): 126–140. doi: 10.1016/j.yd-bio.2009.10.026. Epub 2009 Oct 23.
14. Theocharis AD, Skandalis SS, Gialeli C, Karamanos NK. Extracellular matrix structure. Adv Drug Deliv Rev. 2016 Feb 1; 97: 4–27. doi: 10.1016/j.addr.2015.11.001. Epub 2015 Nov 10.
15. Yang H, Borg TK, Wang Z, Ma Z, Gao BZ. Role of the basement membrane in regulation of cardiac electrical properties. Ann Biomed Eng. 2014 Jun; 42 (6): 1148–1157. doi: 10.1007/s10439-014-0992-x. Epub 2014 Feb 28.
16. Borg TK, Caulfield JB. The collagen matrix of the heart. Fed Proc. 1981 May 15; 40 (7): 2037–2041.
17. Jugdutt BI. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? Circulation. 2003 Sep 16; 108 (11): 1395–1403. doi: 10.1161/01.CIR.0000085658.98621.49.
18. Paltsev MA, Ivanov AA, Severin SE. Intercellular Interactions. M.: Medicine, 2003; 288.
19. Barallobre‑Barreiro J, Lynch M, Yin X, Mayr M. Systems biology-opportunities and challenges: the application of proteomics to study the cardiovascular extracellular matrix. Cardiovasc Res. 2016 Dec; 112 (3): 626–636. doi: 10.1093/cvr/cvw206. Epub 2016 Sep 15.
20. Lapidos KA, Kakkar R, McNally EM. The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ Res. 2004 Apr 30; 94 (8): 1023–1031. doi: 10.1161/01.RES.0000126574.61061.25.
21. French KM, Boopathy AV, DeQuach JA, Chingozha L, Lu H, Christman KL, Davis ME. A naturally derived cardiac extracellular matrix enhances cardiac progenitor cell behavior in vitro. Acta Biomater. 2012 Dec; 8 (12): 4357–4364. doi: 10.1016/j.actbio.2012.07.033. Epub 2012 Jul 27.
22. Loftis MJ, Sexton D, Carver W. Effects of collagen density on cardiac fibroblast behavior and gene expression. J Cell Physiol. 2003 Sep; 196 (3): 504–511. doi: 10.1002/jcp.10330.
23. Jacot JG, Kita‑Matsuo H, Wei KA, Chen HS, Omens JH, Mercola M et al. Cardiac myocyte force development during differentiation and maturation. Ann N Y Acad Sci. 2010 Feb; 1188: 121–127. doi: 10.1111/j.1749-6632.2009.05091.x.
24. Engler AJ, Sen S, Sweeney HL, Discher DE. Matrix elasticity directs stem cell lineage specification. Cell. 2006 Aug 25; 126 (4): 677–689. doi: 10.1016/j.cell.2006.06.044.
25. Miskon A, Mahara A, Uyama H, Yamaoka T. A suspension induction for myocardial differentiation of rat mesenchymal stem cells on various extracellular matrix proteins. Tissue Eng Part C Methods. 2010 Oct; 16 (5): 979–987. doi: 10.1089/ten.TEC.2009.0218.
26. Jacot JG, Martin JC, Hunt DL. Mechanobiology of cardiomyocyte development. J Biomech. 2010 Jan 5; 43 (1): 93–98. doi: 10.1016/j.jbiomech.2009.09.014. Epub 2009 Oct 12.
27. Fomovsky GM, Holmes JW. Evolution of scar structure, mechanics, and ventricular function after myocardial infarction in the rat. Am J Physiol Heart Circ Physiol. 2010 Jan; 298 (1): H221–H228. doi: 10.1152/ajp-heart.00495.2009. Epub 2009 Nov 6.
28. Gjorevski N, Nelson CM. Bidirectional extracellular matrix signaling during tissue morphogenesis. Cytokine Growth Factor Rev. 2009 Oct-Dec; 20 (5–6): 459–465. doi: 10.1016/j.cytogfr.2009.10.013. Epub 2009 Nov 6.
29. Bayomy AF, Bauer M, Qiu Y, Liao R. Regeneration in heart disease – Is ECM the key? Life Sci. 2012 Oct 29; 91 (17–18): 823–827. doi: 10.1016/j.lfs.2012.08.034. Epub 2012 Sep 12.
30. Williams C, Quinn KP, Georgakoudi I, Black LD 3rd. Young developmental age cardiac extracellular matrix promotes the expansion of neonatal cardiomyocytes in vitro. Acta Biomater. 2014 Jan; 10 (1): 194–204. doi: 10.1016/j.actbio.2013.08.037. Epub 2013 Sep 6.
31. Williams C, Sullivan K, Black LD 3rd. Partially Digested Adult Cardiac Extracellular Matrix Promotes Cardiomyocyte Proliferation In Vitro. Adv Healthc Mater. 2015 Jul 15; 4 (10): 1545–1554. doi: 10.1002/adhm.201500035. Epub 2015 May 18. PMID: 25988681; PMCID: PMC4504755.
32. Frangogiannis NG. Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities. Mol Aspects Med. 2019 Feb; 65: 70–99. doi: 10.1016/j.mam.2018.07.001. Epub 2018 Aug 2. PMID: 30056242.
33. De Souza RR. Aging of myocardial collagen. Biogerontology. 2002; 3 (6): 325–335. doi: 10.1023/a:1021312027486. PMID: 12510171.
34. Thomas DP, Cotter TA, Li X, McCormick RJ, Gosselin LE. Exercise training attenuates aging-associated increases in collagen and collagen crosslinking of the left but not the right ventricle in the rat. Eur J Appl Physiol. 2001 Jul; 85 (1–2): 164–169. doi: 10.1007/s004210100447. PMID: 11513311.
35. Frangogiannis NG. Pathophysiology of Myocardial Infarction. Compr Physiol. 2015 Sep 20; 5 (4): 1841–1875. doi: 10.1002/cphy.c150006.
36. Zile MR, Baicu CF, Ikonomidis JS, Stroud RE, Nietert PJ, Bradshaw AD et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation. 2015 Apr 7; 131 (14): 1247–1259. doi: 10.1161/CIRCULATIONAHA.114.013215. Epub 2015 Jan 30.
37. Frangogiannis NG. The extracellular matrix in myocardial injury, repair, and remodeling. J Clin Invest. 2017 May 1; 127 (5): 1600–1612. doi: 10.1172/JCI87491. Epub 2017 May 1.
38. Abbadi D, Laroumanie F, Bizou M, Pozzo J, Daviaud D, Delage C et al. Local production of tenascin-C acts as a trigger for monocyte/macrophage recruitment that provokes cardiac dysfunction. Cardiovasc Res. 2018 Jan 1; 114 (1): 123–137. doi: 10.1093/cvr/cvx221.
39. Christensen G, Herum KM, Lunde IG. Sweet, yet underappreciated: Proteoglycans and extracellular matrix remodeling in heart disease. Matrix Biol. 2019 Jan; 75–76: 286–299. doi: 10.1016/j.matbio.2018.01.001. Epub 2018 Jan 12.
40. Engebretsen KV, Lunde IG, Strand ME, Waehre A, Sjaastad I, Marstein HS et al. Lumican is increased in experimental and clinical heart failure, and its production by cardiac fibroblasts is induced by mechanical and proinflammatory stimuli. FEBS J. 2013 May; 280 (10): 2382–2398. doi: 10.1111/febs.12235. Epub 2013 Apr 2.
41. Beetz N, Rommel C, Schnick T, Neumann E, Lother A, Monroy‑Ordonez EB et al. Ablation of biglycan attenuates cardiac hypertrophy and fibrosis after left ventricular pressure overload. J Mol Cell Cardiol. 2016 Dec; 101: 145–155. doi: 10.1016/j.yjmcc.2016.10.011.
42. Ali SR, Ranjbarvaziri S, Talkhabi M, Zhao P, Subat A, Hojjat A et al. Developmental heterogeneity of cardiac fibroblasts does not predict pathological proliferation and activation. Circ Res. 2014 Sep 12; 115 (7): 625–635. doi: 10.1161/CIRCRESAHA.115.303794.
43. Xia Y, Zhang Y, Shi W, Liu S, Chen Y, Liang X et al. Overexpression of megsin induces mesangial cell proliferation and excretion of type IV collagen in vitro. Cell Immunol. 2011; 271 (2): 413–417. doi: 10.1016/j.cellimm.2011.08.009.
44. Lorenzen JM, Schauerte C, Hübner A, Kölling M, Martino F, Scherf K et al. Osteopontin is indispensible for AP1-mediated angiotensin II-related miR-21 transcription during cardiac fibrosis. Eur Heart J. 2015 Aug 21; 36 (32): 2184–2196. doi: 10.1093/eurheartj/ehv109.
45. Russo I, Cavalera M, Huang S, Su Y, Hanna A, Chen B et al. Protective Effects of Activated Myofibroblasts in the Pressure-Overloaded Myocardium Are Mediated Through Smad-Dependent Activation of a Matrix-Preserving Program. Circ Res. 2019 Apr 12; 124 (8): 1214–1227. doi: 10.1161/CIRCRESAHA.118.314438.
46. Spinale FG, Janicki JS, Zile MR. Membrane-associated matrix proteolysis and heart failure. Circ Res. 2013 Jan 4; 112 (1): 195–208. doi: 10.1161/CIRCRESAHA.112.266882.
47. Saxena A, Chen W, Su Y, Rai V, Uche OU, Li N et al. IL-1 induces proinflammatory leukocyte infiltration and regulates fibroblast phenotype in the infarcted myocardium. J Immunol. 2013 Nov 1; 191 (9): 4838–4848. doi: 10.4049/jimmunol.1300725.
48. Endo K, Takino T, Miyamori H, Kinsen H, Yoshizaki T, Furukawa M et al. Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J Biol Chem. 2003 Oct 17; 278 (42): 40764–40770. doi: 10.1074/jbc.M306736200.
49. González A, López B, Querejeta R, Zubillaga E, Echeverría T, Díez J. Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. Hypertension. 2010 Jun; 55 (6): 1418–1424. doi: 10.1161/HYPERTENSIONAHA.109.149112.
50. DeLeon‑Pennell KY, Meschiari CA, Jung M, Lindsey ML. Matrix Metalloproteinases in Myocardial Infarction and Heart Failure. Prog Mol Biol Transl Sci. 2017; 147: 75–100. doi: 10.1016/bs.pmbts.2017.02.001.
51. Gilbert TW, Sellaro TL, Badylak SF. Decellularization of tissues and organs. Biomaterials. 2006 Jul; 27 (19): 3675–3683. doi: 10.1016/j.biomaterials.2006.02.014.
52. Yahalom‑Ronen Y, Rajchman D, Sarig R, Geiger B, Tzahor E. Reduced matrix rigidity promotes neonatal cardiomyocyte dedifferentiation, proliferation and clonal expansion. Elife. 2015 Aug 12; 4: e07455. doi: 10.7554/eLife.07455.
53. Qiu Y, Bayomy AF, Gomez MV, Bauer M, Du P, Yang Y et al. A role for matrix stiffness in the regulation of cardiac side population cell function. Am J Physiol Heart Circ Physiol. 2015 May 1; 308 (9): H990–H997. doi: 10.1152/ajpheart.00935.2014.
54. Sullivan KE, Black LD. The role of cardiac fibroblasts in extracellular matrix-mediated signaling during normal and pathological cardiac development. J Biomech Eng. 2013 Jul 1; 135 (7): 71001. doi: 10.1115/1.4024349.
55. Sullivan KE, Quinn KP, Tang KM, Georgakoudi I, Black LD 3rd. Extracellular matrix remodeling following myocardial infarction influences the therapeutic potential of mesenchymal stem cells. Stem Cell Res Ther. 2014 Jan 24; 5 (1): 14. doi: 10.1186/scrt403.
56. Dobaczewski M, Bujak M, Zymek P, Ren G, Entman ML, Frangogiannis NG. Extracellular matrix remodeling in canine and mouse myocardial infarcts. Cell Tissue Res. 2006 Jun; 324 (3): 475–488. doi: 10.1007/s00441-005-0144-6.
57. Cleutjens JP, Verluyten MJ, Smiths JF, Daemen MJ. Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol. 1995 Aug; 147 (2): 325–338.
58. Kong P, Shinde AV, Su Y, Russo I, Chen B, Saxena A et al. Opposing Actions of Fibroblast and Cardiomyocyte Smad3 Signaling in the Infarcted Myocardium. Circulation. 2018 Feb 13; 137 (7): 707–724. doi: 10.1161/CIRCULATIONAHA.117.029622.
59. Fu X, Khalil H, Kanisicak O, Boyer JG, Vagnozzi RJ, Maliken BD et al. Specialized fibroblast differentiated states underlie scar formation in the infarcted mouse heart. J Clin Invest. 2018 May 1; 128 (5): 2127–2143. doi: 10.1172/JCI98215.
60. Chen B, Frangogiannis NG. Macrophages in the Remodeling Failing Heart. Circ Res. 2016 Sep 16; 119 (7): 776–778. doi: 10.1161/CIRCRESAHA.116.309624.
61. Sager HB, Hulsmans M, Lavine KJ, Moreira MB, Heidt T, Courties G et al. Proliferation and Recruitment Contribute to Myocardial Macrophage Expansion in Chronic Heart Failure. Circ Res. 2016 Sep 16; 119 (7): 853–864. doi: 10.1161/CIRCRESAHA.116.309001.
62. Chen JH, Simmons CA. Cell-matrix interactions in the pathobiology of calcific aortic valve disease: critical roles for matricellular, matricrine, and matrix mechanics cues. Circ Res. 2011 Jun 10; 108 (12): 1510–1524. doi: 10.1161/CIRCRESAHA.110.234237.
63. Xia Y, Dobaczewski M, Gonzalez‑Quesada C, Chen W, Biernacka A, Li N et al. Endogenous thrombospondin 1 protects the pressure-overloaded myocardium by modulating fibroblast phenotype and matrix metabolism. Hypertension. 2011 Nov; 58 (5): 902–911. doi: 10.1161/HYPERTENSIONAHA.111.175323.
64. Frangogiannis NG. Matricellular proteins in cardiac adaptation and disease. Physiol Rev. 2012 Apr; 92 (2): 635–688. doi: 10.1152/physrev.00008.2011.
65. Schellings MW, Vanhoutte D, Swinnen M, Cleutjens JP, Debets J, van Leeuwen RE et al. Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction. J Exp Med. 2009 Jan 16; 206 (1): 113–123. doi: 10.1084/jem.20081244.
66. Hynes RO, Naba A. Overview of the matrisome – an inventory of extracellular matrix constituents and functions. Cold Spring Harb Perspect Biol. 2012 Jan 1; 4 (1): a004903. doi: 10.1101/cshperspect.a004903.
67. Valentin JE, Stewart‑Akers AM, Gilbert TW, Badylak SF. Macrophage participation in the degradation and remodeling of extracellular matrix scaffolds. Tissue Eng Part A. 2009 Jul; 15 (7): 1687–1694. doi: 10.1089/ten.tea.2008.0419.
68. Lindsey ML, Iyer RP, Zamilpa R, Yabluchanskiy A, DeLeon‑Pennell KY, Hall ME et al. A Novel Collagen Matricryptin Reduces Left Ventricular Dilation Post-Myocardial Infarction by Promoting Scar Formation and Angiogenesis. J Am Coll Cardiol. 2015 Sep 22; 66 (12): 1364–1374. doi: 10.1016/j.jacc.2015.07.035.
69. Ricard‑Blum S, Salza R. Matricryptins and matrikines: biologically active fragments of the extracellular matrix. Exp Dermatol. 2014 Jul; 23 (7): 457–463. doi: 10.1111/exd.12435.
70. Agrawal V, Tottey S, Johnson SA, Freund JM, Siu BF, Badylak SF. Recruitment of progenitor cells by an extracellular matrix cryptic peptide in a mouse model of digit amputation. Tissue Eng Part A. 2011 Oct; 17 (19–20): 2435–2443. doi: 10.1089/ten.TEA.2011.0036.
71. Carey LE, Dearth CL, Johnson SA, Londono R, Medberry CJ, Daly KA et al. In vivo degradation of 14C-labeled porcine dermis biologic scaffold. Biomaterials. 2014 Sep; 35 (29): 8297–8304. doi: 10.1016/j.biomaterials.2014.06.015.
72. Dziki JL, Sicari BM, Wolf MT, Cramer MC, Badylak SF. Immunomodulation and Mobilization of Progenitor Cells by Extracellular Matrix Bioscaffolds for Volumetric Muscle Loss Treatment. Tissue Eng Part A. 2016 Oct; 22 (19–20): 1129–1139. doi: 10.1089/ten.TEA.2016.0340.
73. Keane TJ, Londono R, Turner NJ, Badylak SF. Consequences of ineffective decellularization of biologic scaffolds on the host response. Biomaterials. 2012 Feb; 33 (6): 1771–1781. doi: 10.1016/j.biomaterials.2011.10.054.
74. Sicari BM, Dziki JL, Siu BF, Medberry CJ, Dearth CL, Badylak SF. The promotion of a constructive macrophage phenotype by solubilized extracellular matrix. Biomaterials. 2014 Oct; 35 (30): 8605–8612. doi: 10.1016/j.biomaterials.2014.06.060.
75. Brown BN, Londono R, Tottey S, Zhang L, Kukla KA, Wolf MT et al. Macrophage phenotype as a predictor of constructive remodeling following the implantation of biologically derived surgical mesh materials. Acta Biomater. 2012 Mar; 8 (3): 978–987. doi: 10.1016/j.act-bio.2011.11.031.
76. Reing JE, Zhang L, Myers‑Irvin J, Cordero KE, Freytes DO, Heber‑Katz E et al. Degradation products of extracellular matrix affect cell migration and proliferation. Tissue Eng Part A. 2009 Mar; 15 (3): 605–614. doi: 10.1089/ten.tea.2007.0425.
77. Vorotnikova E, McIntosh D, Dewilde A, Zhang J, Reing JE, Zhang L et al. Extracellular matrix-derived products modulate endothelial and progenitor cell migration and proliferation in vitro and stimulate regenerative healing in vivo. Matrix Biol. 2010 Oct; 29 (8): 690–700. doi: 10.1016/j.matbio.2010.08.007.
78. Liu W, Zhang X, Zhao M, Zhang X, Chi J, Liu Y et al. Activation in M1 but not M2 Macrophages Contributes to Cardiac Remodeling after Myocardial Infarction in Rats: a Critical Role of the Calcium Sensing Receptor/ NRLP3 Inflammasome. Cell Physiol Biochem. 2015; 35 (6): 2483–2500. doi: 10.1159/000374048.
79. Dziki JL, Giglio RM, Sicari BM, Wang DS, Gandhi RM, Londono R et al. The Effect of Mechanical Loading Upon Extracellular Matrix Bioscaffold-Mediated Skeletal Muscle Remodeling. Tissue Eng Part A. 2018 Jan; 24 (1–2): 34–46. doi: 10.1089/ten.TEA.2017.0011.
80. Sadtler K, Estrellas K, Allen BW, Wolf MT, Fan H, Tam AJ et al. Developing a pro-regenerative biomaterial scaffold microenvironment requires T helper 2 cells. Science. 2016 Apr 15; 352 (6283): 366–370. doi: 10.1126/science.aad9272.
81. Lebedeva AI, Muslimov SA, Gareev EM, Afanasiev SA, Condratyeva DS, Popov SV. Macrophages as homeostatic regulators in the ischemically damaged myocardium after use of allogenic biomaterial. Bulletin of Siberian medicine. 2020; 19 (1): 67–75. doi: 10.20538/1682-0363-2020-1-67-75.
82. Jiang H, Sun X, Liu J, Fang L, Liang Y, Zhou J et al. Decellularized Extracellular Matrix Scaffold Loaded with Regulatory T Cell-Conditioned Medium Induces M2 Macrophage Polarization. Biomater Res. 2025 Apr 18; 29: 0196. doi: 10.34133/bmr.0196.
83. Wynn TA, Vannella KM. Macrophages in Tissue Repair, Regeneration, and Fibrosis. Immunity. 2016 Mar 15; 44 (3): 450–462. doi: 10.1016/j.immuni.2016.02.015.
84. Van den Bosch TP, Caliskan K, Kraaij MD, Constantinescu AA, Manintveld OC, Leenen PJ et al. CD16+ Monocytes and Skewed Macrophage Polarization toward M2 Type Hallmark Heart Transplant Acute Cellular Rejection. Front Immunol. 2017 Mar 24; 8: 346. doi: 10.3389/fimmu.2017.00346.
85. Kaplan A, Altara R, Eid A, Booz GW, Zouein FA. Update on the Protective Role of Regulatory T Cells in Myocardial Infarction: A Promising Therapy to Repair the Heart. J Cardiovasc Pharmacol. 2016 Dec; 68 (6): 401–413. doi: 10.1097/FJC.0000000000000436.
86. Lebedeva AI, Muslimov SA, Gareev EM, Popov SV, Afanas’ev SA, Kondrat’eva DS. Experimental cardiomyogenesis under conditions of administration of different doses of the allogeneic biomaterial. Bulletin of Experimental Biology and Medicine. 2018: 165 (6): 790–792.
87. Muldashev ER, Lebedeva AI, Muslimov SA, Popov SV, Afanasyev SA, Kondratieva DS. Allogenic biomaterial – an inducer of autologous stem and committed myocardial cells in ischemic damaged myocardium. Practical medicine. 2019; 1: 89–94.
88. Lebedeva AI, Muslimov SA, Gareev EM, Popov SV, Afanasiev SA. Stimulation of autologous progenitorial and committed cells in ischemically damaged myocardium. Russian journal of cardiology. 2018; 23 (11): 123–129. doi: 10.15829/1560-4071-2018-11-123-129.
89. Shakhov VP, Afanasiev SA, Popov SV. Possibble role of circulating multipotent stem cells in development of atherosclerosis. Kardiologiia. 2005; 8: 51–52.
90. Spang MT, Middleton R, Diaz M, Hunter J, Mesfin J, Banka A et al. Intravascularly infused extracellular matrix as a biomaterial for targeting and treating inflamed tissues. Nat Biomed Eng. 2023 Feb; 7 (2): 94–109. doi: 10.1038/s41551-022-00964-5.
91. Chen A, Mesfin JM, Gianneschi NC, Christman KL. Intravascularly Deliverable Biomaterial Platforms for Tissue Repair and Regeneration Post-Myocardial Infarction. Adv Mater. 2024 Oct; 36 (43): e2300603. doi: 10.1002/adma.202300603.
92. Mesfin JM, Ninh VK, Diaz MD, Nguyen MB, Chen A, Wang RM et al. Uncovering the Regional and Cell Specific Bioactivity of Injectable Extracellular Matrix Biomaterials in Myocardial Infarction through Spatial and Single Nucleus Transcriptomics. bioRxiv [Preprint]. 2025 Jun 27: 2025.06.25.661525. doi: 10.1101/2025.06.25.661525. Update in: Nat Commun. 2025 Nov 24; 16 (1): 10387. doi: 10.1038/s41467-025-65351-5.
93. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015 Jan; 20 (1): 122–128. doi: 10.1016/j.drudis.2014.10.003.
94. Daley MC, Fenn SL, Black LD 3rd. Applications of Cardiac Extracellular Matrix in Tissue Engineering and Regenerative Medicine. Adv Exp Med Biol. 2018; 1098: 59–83. doi: 10.1007/978-3-319-97421-7.
95. Afanasiev SA, Kondratieva DS, Lebedeva AI, Muslimov SA, Popov SV. Functional state of myocardium after application of a non-cellular allogenic material for stimulation of regeneration capacity in experimental infarction. Russian journal of cardiology. 2018; 23 (3): 71–75. doi: 10.15829/1560-4071-2018-3-71-75.
96. Afanasiev SA, Kondratyeva DS, Usov VYu, Lebedeva AI, Muslimov SA, Popov SV. Prevention of post-infarction cardiac remodeling after using the non-cellular biomaterial in the experiment. Russian journal of cardiology. 2019; 24 (7): 63–67. doi: 10.15829/1560-4071-2019-7-63-67.
97. Lebedeva AI, Muslimov SA, Gareev EM, Popov SV, Afanasiev SA, Kondratieva DS. Metalloproteases and inhibitors expression in myocardium under ischemic conditions after allogenic biomaterial introduction. Russian journal of cardiology. 2018; 23 (7): 73–79. doi: 10.15829/1560-4071-2018-7-73-79.
98. Lebedeva AI, Muslimov SA, Musina LA, Gareev EM, Kadyrov RZ, Condratyeva DS et al. Effect of intramyocardial allogenic biomaterial injection on angiogenesis and postischemic scar remodeling in rats. Russian journal of transplantology and artificial organs. 2020; 3: 156–166. doi: 10.15825/1995-1191-2020-3-156-166.
99. Lebedeva AI, Muslimov SA, Shangina OR, Afanasiev SA, Kondratyeva DS, Popov SV. Effect of allogeneic biomaterial on scar remodeling in the subacute stage of myocardial infarction. Russian journal of transplantology and artificial organs. 2019; 5: 166.
100. Lebedeva AI, Afanasiev SA, Kondratyeva DS, Gareev EM, Muslimov SA, Popov SV. Correction of cicatricial changes in subacute stage of myocardial infarction with using of dispersed allogenic biomaterial. Russian journal of cardiology. 2019; 24 (7): 68–74. doi: 10.15829/1560-4071-2019-7-68-74.
101. Kawecki M, Łabuś W, Klama‑Baryla A, Kitala D, Kraut M, Glik J et al. A review of decellurization methods caused by an urgent need for quality control of cell-free extracellular matrix’ scaffolds and their role in regenerative medicine. J Biomed Mater Res B Appl Biomater. 2018 Feb; 106 (2): 909–923. doi: 10.1002/jbm.b.33865.
102. Jiang Y, Li R, Han C, Huang L. Extracellular matrix grafts: From preparation to application (Review). Int J Mol Med. 2021 Feb; 47 (2): 463–474. doi: 10.3892/ijmm.2020.4818.
103. Keane TJ, Badylak SF. The host response to allogeneic and xenogeneic biological scaffold materials. J Tissue Eng Regen Med. 2015 May; 9 (5): 504–511. doi: 10.1002/term.1874.
104. Cramer MC, Badylak SF. Extracellular Matrix-Based Biomaterials and Their Influence Upon Cell Behavior. Ann Biomed Eng. 2020 Jul; 48 (7): 2132–2153. doi: 10.1007/s10439-019-02408-9.
105. Dziki JL, Badylak SF. Extracellular Matrix for Myocardial Repair. Adv Exp Med Biol. 2018; 1098: 151–171. doi: 10.1007/978-3-319-97421-7.
106. Saldin LT, Cramer MC, Velankar SS, White LJ, Badylak SF. Extracellular matrix hydrogels from decellularized tissues: Structure and function. Acta Biomater. 2017 Feb; 49: 1–15. doi: 10.1016/j.actbio.2016.11.068. Epub 2016 Dec 1. PMID: 27915024; PMCID: PMC5253110.
107. Seif‑Naraghi SB, Singelyn JM, Salvatore MA, Osborn KG, Wang JJ, Sampat U et al. Safety and efficacy of an injectable extracellular matrix hydrogel for treating myocardial infarction. Sci Transl Med. 2013 Feb 20; 5 (173): 173ra25. doi: 10.1126/scitranslmed.3005503.
108. Sonnenberg SB, Rane AA, Liu CJ, Rao N, Agmon G, Suarez S et al. Delivery of an engineered HGF fragment in an extracellular matrix-derived hydrogel prevents negative LV remodeling post-myocardial infarction. Biomaterials. 2015 Mar; 45: 56–63. doi: 10.1016/j.biomaterials.2014.12.021.
109. Akbarzadeh A, Sabetkish S, Kajbafzadeh AM. Cardiac Extracellular Matrix as a Platform for Heart Organ Bioengineering: Design and Development of Tissue-Engineered Heart. Adv Exp Med Biol. 2021; 1345: 47–59. doi: 10.1007/978-3-030-82735-9.
110. Wang Z, Long DW, Huang Y, Chen WCW, Kim K, Wang Y. Decellularized neonatal cardiac extracellular matrix prevents widespread ventricular remodeling in adult mammals after myocardial infarction. Acta Biomater. 2019 Mar 15; 87: 140–151. doi: 10.1016/j.act-bio.2019.01.062.
111. Belviso I, Angelini F, Di Meglio F, Picchio V, Sacco AM, Nocella C et al. The Microenvironment of Decellularized Extracellular Matrix from Heart Failure Myocardium Alters the Balance between Angiogenic and Fibrotic Signals from Stromal Primitive Cells. Int J Mol Sci. 2020 Oct 24; 21 (21): 7903. doi: 10.3390/ijms21217903.
112. Liguori GR, Liguori TTA, de Moraes SR, Sinkunas V, Terlizzi V, van Dongen JA et al. Molecular and Biomechanical Clues From Cardiac Tissue Decellularized Extracellular Matrix Drive Stromal Cell Plasticity. Front Bioeng Biotechnol. 2020 May 29; 8: 520. doi: 10.3389/fbioe.2020.00520.
113. Федеральный Закон № 180 РФ (ФЗ № 180) «О биомедицинских клеточных продуктах». 2017; пп. 33 и 35. Federal Law № 180 of the Russian Federation (FL № 180) «On Biomedical Cell Products». 2017; paragraphs 33 and 35.
114. Akhmedov ShD, Afanasyev SA, Dyakova ML, Fatkhutdinov TKh, Kaktursky LV. The use of a cell-free matrix for the formation of new blood vessels and the heart by tissue engineering. Cellular Transplantation and Tissue Engineering. 2009; 4 (2): 32–39.
115. Akbarzadeh A, Sobhani S, Soltani Khaboushan A, Kajbafzadeh AM. Whole-Heart Tissue Engineering and Cardiac Patches: Challenges and Promises. Bioengineering (Basel). 2023 Jan 12; 10 (1): 106. doi: 10.3390/bioengineering10010106.
116. Franco‑Barraza J, Beacham DA, Amatangelo MD, Cukierman E. Preparation of Extracellular Matrices Produced by Cultured and Primary Fibroblasts. Curr Protoc Cell Biol. 2016 Jun 1; 71: 10.9.1–10.9.34. doi: 10.1002/cpcb.2.
117. Parmaksiz M, Elçin AE, Elçin YM. Decellularized Cell Culture ECMs Act as Cell Differentiation Inducers. Stem Cell Rev Rep. 2020 Jun; 16 (3): 569–584. doi: 10.1007/s12015-020-09963-y.
118. Schaart JM, Kea‑Te Lindert M, Roverts R, Nijhuis WH, Sommerdijk N, Akiva A. Cell-induced collagen alignment in a 3D in vitro culture during extracellular matrix production. J Struct Biol. 2024 Jun; 216 (2): 108096. doi: 10.1016/j.jsb.2024.108096.
119. Phothichailert S, Samoun S, Fournier BP, Isaac J, Nelwan SC, Osathanon T et al. MSCs-Derived Decellularised Matrix: Cellular Responses and Regenerative Dentistry. Int Dent J. 2024 Jun; 74 (3): 403–417. doi: 10.1016/j.identj.2024.02.011.
120. Muthuchamy M, Subramanian K, Padhiar C, Dhanraj AK, Desireddy S. Feasibility study on intact human umbilical cord Wharton’s jelly as a scaffold for human autologous chondrocyte: In-vitro study. Int J Artif Organs. 2022 Nov; 45 (11): 936–944. doi: 10.1177/03913988221118102.
121. Kondratenko AA, Tovpeko DV, Volov DA, Kalyuzhnaya LI, ChernovVE, Glushakov RI et al. Decellularized Umbilical Cord as a Scaffold to Support Healing of Full-Thickness Wounds. Biomimetics. 2024; 9 (7): 405–424. doi: 10.3390/biomimetics9070405.
122. Li Y, Zhang Y, Zhang G. Comparative Analysis of Decellularization Methods for the Production of Decellularized Umbilical Cord Matrix. Curr Issues Mol Biol. 2024 Jul 19; 46 (7): 7686–7701. doi: 10.3390/cimb46070455.
123. Abbaszadeh H, Ghorbani F, Derakhshani M, Movassaghpour AA, Yousefi M, Talebi M et al. Regenerative potential of Wharton’s jelly-derived mesenchymal stem cells: A new horizon of stem cell therapy. J Cell Physiol. 2020 Dec; 235 (12): 9230–9240. doi: 10.1002/jcp.29810.
124. Aratikatla A, Maffulli N, Gupta M, Potti IA, Potty AG, Gupta A. Wharton’s jelly and osteoarthritis of the knee. Br Med Bull. 2024 Mar 13; 149 (1): 13–31. doi: 10.1093/bmb/ldad030.
125. Chao NN, Li JL, Ding W, Qin TW, Zhang Y, Xie HQ et al. Fabrication and characterization of a pro-angiogenic hydrogel derived from the human placenta. Biomater Sci. 2022 Apr 12; 10 (8): 2062–2075. doi: 10.1039/d1bm01891d.
126. Francis MP, Breathwaite E, Bulysheva AA, Varghese F, Rodriguez RU, Dutta S et al. Human placenta hydrogel reduces scarring in a rat model of cardiac ischemia and enhances cardiomyocyte and stem cell cultures. Acta Biomater. 2017 Apr 1; 52: 92–104. doi: 10.1016/j.act-bio.2016.12.027.
127. Gamba LK, Gamba LK, da Costa C, Takejima AL, Simeoni RB, Rossa ICM et al. Wharton’s Jelly Bioscaffolds Improve Cardiac Repair with Bone Marrow Mononuclear Stem Cells in Rats. Journal of Functional Biomaterials. 2025; 16 (5): 175. https://doi.org/10.3390/jfb16050175.
128. Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ et al. Mesenchymal stem cells in the Wharton’s jelly of the human umbilical cord. Stem Cells. 2004; 22 (7): 1330–1337. doi: 10.1634/stemcells.2004-0013.
129. Nishiyama N, Miyoshi S, Hida N, Uyama T, Okamoto K, Ikegami Y et al. The significant cardiomyogenic potential of human umbilical cord blood-derived mesenchymal stem cells in vitro. Stem cells. 2007; 25: 2017–2024. doi: 10.1634/stemcells.2006-0662.
130. Kalyuzhnaya LI, Chernov VE, Frumkina AS, Chebotarev SV, Zemlyanoy DA, Tovpeko DV et al. Fabrication of human wharton’s jelly extra cellular matrix for tissue engineering. Bulletin of the russian military medical academy. 2020; 1 (69): 124–130. doi: 10.17816/brmma25980.
131. Kalyuzhnaya LI, Sokolova MO, Chernov VE, Zemlyanoy DA, Chebotarev SV, Chalisova NI et al. The effect of the cell-free matrix of the human umbilical cord on the growth dynamics and viability of cultured human and animal cells ex vivo. Genes & Cells. 2021; 16 (3): 72–79. doi: 10.23868/202110010.
132. Chebotarev SV, Kalyuzhnaya LI, Khominets VV, Chernov VE, Frumkina AS, Zemlyanoy DA et al. Regenerative effects of human umbilical cord hydrogel in the treatment of articular cartilage injuries. Clinical and experimental surgery. Petrovsky journal. 2020; 8 (4 (30)): 119–125. doi: 10.33029/2308-1198-2020-8-4-119-125.
Review
For citations:
Afanasiev S.A., Zakopayko B.A., Kondratieva D.S., Zemlyanoy D.A., Raguzina D.V., Popov S.V. Prospects for allogeneic acellular tissue-engineered products in the management of post-ischemic myocardial remodeling. Russian Journal of Transplantology and Artificial Organs. 2026;28(2):188-201. (In Russ.) https://doi.org/10.15825/1995-1191-2026-2-188-201
Views:
46
JATS XML
Email this article 